Crossmark

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4

Crossref DOI link: https://doi.org/10.1038/s41408-019-0173-0

Published Online: 2019-02-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhu, Yuan Xiao

Shi, Chang-Xin

Bruins, Laura A.

Wang, Xuewei

Riggs, Daniel L.

Porter, Brooke

Ahmann, Jonathan M.

de Campos, Cecilia Bonolo

Braggio, Esteban

Bergsagel, P. Leif https://orcid.org/0000-0003-1523-7388
Stewart, A. Keith
Funding

Funding for this research was provided by:

DH | National Institute for Health Research (RO1CA183968-01A)
License Information

Text and Data Mining valid from 2019-02-11

Version of Record valid from 2019-02-11
More Information

Article History

Received: 10 July 2018

Revised: 16 November 2018

Accepted: 21 November 2018

First Online: 11 February 2019

Conflict of interest

: A.K.S. was consultant for Bristol-Myers Squibb, Celgene, Amgen, Janssen, Takeda, and Roche. The remaining authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below